ArticleFrontiers in endocrinology2025
Case Report: Falsely elevated PTH level in a young woman caused by immunoassay interference resulting from macro-PTH.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Visual Ecology ofAnimals : an open access journal from MDPI · 2026Review
- Macrohormones in endocrinology: prevalence, clinical impact, and diagnostic approaches.Frontiers in endocrinology · 2026Review
- Parathyroid hormone assay standardization in CKD-MBD: resolving heterogeneity for precision medicine.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated parathyroid hormone (PTH) levels usually suggest an underlying parathyroid disorder. However, immunoassay interference, such as macro-PTH, can result in falsely elevated readings, leading to diagnostic inaccuracy. Here, we report the case of a 27-year-old woman with persistently elevated PTH levels despite normal serum calcium, phosphate, and vitamin D. Aside from a history of nephrolithiasis, the patient was asymptomatic and exhibited no parathyroid abnormalities detected on ultrasound, sestamibi scintigraphy, or choline positron emission tomography-computed tomography (PET-CT) scans. To investigate potential immunoassay interference, a polyethylene glycol (PEG) 6000 precipitation assay was performed, which showed a decrease of PTH levels from >1200 pg/mL to approximately 40 pg/mL, corresponding to a 97% reduction. To validate the specificity of this technique, the same procedure was conducted on sera from two patients with elevated PTH levels due to known parathyroid pathologies. PTH levels decreased from 771 to 271 pg/ml and 527 to 146 pg/ml, corresponding to 65 and 72% reduction, respectively. The following results indicated that the PEG precipitation primarily affected the macro-PTH in our patient's sample while leaving intact PTH relatively unaffected in the control group. This report suggests that unexpectedly high PTH levels in the presence of otherwise normal laboratory values and imaging results could indicate the possibility of immunoassay interference. PEG 6000 precipitation is a valuable diagnostic tool for macro-PTH detection, although further refinement of immunoassay techniques may be needed to enhance the reliability of PTH measurements in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.